Medscape20h
Subcutaneous Guselkumab Proves Efficacious for IBD in Two Studies: ASTRO and GRAVITI
For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...
manilatimes19h
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: "I'm excited for the opportunity to follow-up on ...
Santé log12h
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis
Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.